Abstract
Introduction: Taurine has a prominent lipid-lowering effect on hyperlipidemia. However, a comprehensive analysis of the effects of taurine on endogenous metabolites in hyperlipidemia has not been documented. This study aimed to explore the impact of taurine on multiple metabolites associated with hyperlipidemia.
Methods: The hyperlipidemic mouse model was induced by high-fat diet (HFD). Taurine was administered via oral gavage at doses of 700 mg/kg/day for 14 weeks. Evaluation of body weight, serum lipid levels, and histopathology of the liver and adipose tissue was performed to confirm the lipid-lowering effect of taurine. Ultra-high performance liquid chromatography-mass spectrometry (UPLC-MS)-based metabonomics analyses of serum, urine, feces, and liver, coupled with multivariate data analysis, were conducted to assess changes in the endogenous metabolites.
Results and discussion: Biochemical and histological examinations demonstrated that taurine administration prevented weight gain and dyslipidemia, and alleviated lipid deposition in the liver and adipose tissue in hyperlipidemic mice. A total of 76 differential metabolites were identified, mainly involving bile acids, glycerophospholipids, sphingomyelins, diglycerides, triglycerides, polyunsaturated fatty acids, and amino acids. Taurine effectively alleviates metabolic abnormalities caused by HFD, including fatty acid metabolism, sphingolipid metabolism, and bile acid metabolism. This study provides new evidence for taurine to prevent hyperlipidemia.
Introduction
Hyperlipidemia is a primary driver of cardiovascular disease and type 2 diabetes. While pharmacological interventions like statins are effective, they often come with significant side effects. Taurine, a conditionally essential amino acid found abundantly in seafood, has long been recognized for its lipid-lowering properties. However, the exact metabolic mechanisms have remained unclear. This study seeks to fill that gap by performing a comprehensive, multi-organ metabolomic analysis to see how taurine reshapes the metabolic landscape in hyperlipidemic mice.
Methods
The researchers employed a C57BL/6J mouse model, inducing hyperlipidemia via a high-fat diet (HFD) over 14 weeks. One group received a daily oral dose of 700 mg/kg of taurine. The core of the study is an untargeted metabolomics approach using Ultra-High Performance Liquid Chromatography-Mass Spectrometry (UPLC-MS) to analyze serum, liver, urine, and feces. To identify the detected molecules, the authors compared their MS/MS spectra against established biochemical databases like HMDB, METLIN, and KEGG.
Results
Physiological Impact and Histopathology
Taurine significantly prevented weight gain and improved serum lipid profiles. It lowered total cholesterol (TC), triglycerides (TG), and LDL-C, while preventing the drop in "good" HDL-C. Histopathological analysis of liver and adipose tissue showed a dramatic reduction in lipid droplets and vacuoles in the taurine-treated group compared to the HFD-only group.
Metabolic Insights
The team identified 76 differential metabolites across the four sample types. Key findings include:
- Lipotoxicity Reduction: Taurine reduced Diglycerides (DGs) in the liver, which are known to interfere with insulin signaling.
- Bile Acid Excretion: Taurine accelerates the conversion of cholesterol into bile acids and increases their fecal excretion, facilitating cholesterol breakdown.
- Restoring Beneficial Fats: Taurine supplementation helped restore levels of beneficial Polyunsaturated Fatty Acids (PUFAs) like DHA.
Discussion and Conclusion
Taurine acts as a metabolic "switch," shifting the body from fat synthesis to fat breakdown. By lowering lipotoxic DGs and restoring amino acid and lipid homeostasis, taurine provides a multi-layered defense against hyperlipidemia. While these results are promising, clinical trials are needed to confirm these mechanisms in humans, as metabolic rates differ significantly between species. This study provides a high-resolution map of metabolic changes, identifying potential biomarkers and therapeutic targets for future hyperlipidemia research.
Summary updated